Piotr Ciechanowicz
Warsaw, MZ 02507, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Targeted Radiotherapy in Primary Cutaneous Lymphomas: Precision, Efficacy, and Evolving Strategies.
Journal: Cancers
Published: July 11, 2025
Cardiovascular Magnetic Resonance Imaging in Physically Fit Young Patients Sans Comorbidities Who Recently Recovered from Coronavirus Disease 2019 (COVID-19).
Journal: Annals of agricultural and environmental medicine : AAEM
Published: September 30, 2024
Should the Dermatological Assessment of Patients with Inflammatory Bowel Disease Become Standard during Qualifications for Biological Treatment? A Retrospective, Single-Center Experience from a Tertiary Center.
Journal: Journal of clinical medicine
Published: July 31, 2024
Dermal lesions associated with anti-tumor necrosis factor α therapy in patients with inflammatory bowel disease (IBD): findings from a tertiary IBD center in Poland.
Journal: Polish archives of internal medicine
Published: July 01, 2024
Evaluation of elafin as a marker of skin fibrosis -a preliminary study.
Journal: Archives of dermatological research
Published: December 19, 2023
Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland.
Journal: Journal of clinical medicine
Published: January 28, 2023
Skin manifestations of neuroendocrine neoplasms: review of the literature.
Journal: Postepy dermatologii i alergologii
Published: November 09, 2021
The Role of Epigenetic Factors in Psoriasis.
Journal: International journal of molecular sciences
Published: July 26, 2021
Hidradenitis suppurativa - biologic therapy and other available treatment options.
Journal: Postepy dermatologii i alergologii
Published: July 19, 2021
Psychological consequences of hospital isolation during the COVID-19 pandemic - research on the sample of polish firefighting academy students.
Journal: Current psychology (New Brunswick, N.J.)
Published: June 07, 2021
Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Journal: Postepy dermatologii i alergologii
Published: April 26, 2021
Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Journal: Dermatologic therapy
Published: March 05, 2021
Last Updated: 09/26/2026